Curewell Capital Acquires Majority Stake in Wilmington PharmaTech

Wilmington PharmaTech (WPT), a manufacturer of small molecule active pharmaceutical ingredients (API) based in the United States, has entered into a significant agreement with Los Angeles–based private equity firm Curewell Capital. This investment involves Curewell acquiring a majority stake in WPT, with the objective of driving the company’s expansion and enhancing its domestic manufacturing capabilities.

The transaction positions Wilmington PharmaTech to capitalize on the increasing demand for specialized pharmaceutical manufacturing within the United States. Hui-Yin “Harry” Li, Ph.D., the founder and CEO of WPT, will maintain a considerable ownership stake and continue to lead the company in collaboration with its existing management team.

Curewell Capital’s involvement is expected to provide WPT with substantial growth capital, which will be used to expand its manufacturing footprint and improve its end-to-end API development and production services. Since its establishment in 2003, WPT has built a reputation as a trusted partner for global drug developers, offering integrated services that span discovery, clinical development, and commercial-scale manufacturing.

Expansion Plans and Market Demand

Wilmington PharmaTech operates from a 54-acre campus in Delaware, which features two state-of-the-art facilities equipped with current Good Manufacturing Practices (cGMP) and high potency API suites. Additionally, the company has an R&D center located in Suzhou, China.

Dr. Li expressed optimism about the partnership, stating, “Together with Curewell Capital, we look forward to accelerating our growth strategy by leveraging our core competencies. We are committed to expanding our capabilities and capacity to better serve our global biopharmaceutical partners.”

Curewell Capital partner Michael Dal Bello commended WPT’s scientific depth and operational excellence. He highlighted that the investment comes at a time when there is a significant rise in demand for reliable, high-quality pharmaceutical manufacturing in the U.S. “Our investment will help WPT accelerate its next phase of growth amid strong market demand for dependable, high-quality capacity,” Dal Bello noted.

Wilmington PharmaTech’s strategic move is designed to enhance its role as a key U.S. manufacturing partner for biopharmaceutical innovators, allowing the company to meet both domestic and international market needs for advanced API development.

As the pharmaceutical sector continues to evolve, this partnership is expected to position Wilmington PharmaTech advantageously, ensuring it remains at the forefront of the industry and capable of responding to the growing needs of its global partners.